Home・Lista de Ações・Cogent Biosciences Inc

Cogent Biosciences Inc

Fechado

34.68 -6.19

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

34.46

Máximo

34.79

Indicadores-chave
By Trading Economics
Rendimento	947K -96M
EPS	-0.52
Funcionários	258
EBITDA	537K -94M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+55.35% upside

Dividendos
By Acuity
Próximos Ganhos	2 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-353M 6.3B
Abertura anterior	40.87
Fecho anterior	34.68

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de ago. de 2026, 23:51 UTC

"Bitcoin and Ethereum Rise Amid Market Uncertainty; Barclays Warns of Commodity Shock, Fed Signals Possible Rate Hikes, and Canada's GDP Growth Falls Short of Expectations."

29 de ago. de 2026, 23:51 UTC

Bitcoin and Ethereum rise amid economic uncertainties, while Barclays warns of a commodity shock and Fed Chair hints at potential interest rate hikes.

29 de ago. de 2026, 23:51 UTC

Cryptocurrency gains amid economic uncertainty; Barclays warns of commodity shock from El Niño, while Fed signals potential rate hikes and Canada faces trade tensions.

29 de ago. de 2026, 23:51 UTC

Cryptocurrency gains amid economic uncertainty, while Barclays warns of commodity shocks and Fed signals potential rate hikes, impacting U.S. stock markets and Canadian trade tensions.

29 de ago. de 2026, 23:41 UTC

U.S. Import Data Release on September 3, 2026 Expected to Reflect Impact of Tariff Changes Amid Escalating Trade Tensions with Canada.

29 de ago. de 2026, 23:41 UTC

U.S. Trade Deficit Expected to Widen to $86.4 Billion Amid Ongoing Tariff Tensions with Canada

29 de ago. de 2026, 23:41 UTC

Mexican Business Confidence Remains Low Ahead of September Survey, Anticipating Continued Economic Challenges

29 de ago. de 2026, 23:41 UTC

U.S. July 2026 export data release on September 3 expected to reflect ongoing trade challenges amid U.S.-Canada tariff tensions, raising market volatility concerns.

29 de ago. de 2026, 23:41 UTC

Canada's Balance of Trade Expected to Show C$3.2 Billion Surplus Amid Rising U.S.-Canada Tariff Tensions

29 de ago. de 2026, 23:31 UTC

Brazil's Q2 2026 GDP Growth Rate Release on September 1st Sparks Cautious Optimism Amid Economic Challenges and Global Trade Tensions.

29 de ago. de 2026, 23:31 UTC

South Africa's Balance of Trade report on August 31 expected to reveal if trade surplus continues amid concerns over El Niño impacts and global commodity markets.

29 de ago. de 2026, 23:11 UTC

ADP Employment Change report on September 2 forecasts a modest increase of 47,000 jobs amid cautious labor market sentiment and potential downward revisions in nonfarm payrolls.

29 de ago. de 2026, 23:11 UTC

Mexican Consumer Confidence Index Set for Release on September 3, Amid Global Economic Uncertainty and Mixed Sentiments.

29 de ago. de 2026, 23:01 UTC

Macro News

DAX 30 Index declines in after-market hours, pressured by hawkish Fed remarks and geopolitical tensions. The index remains near its one-month low.

29 de ago. de 2026, 22:52 UTC

Japan's Household Spending Data Release Sparks Caution Amid Rising Inflation Concerns and Weak Investor Confidence

29 de ago. de 2026, 22:52 UTC

Japan's Household Spending Expected to Decline by -1.6% YoY Amid Inflation Concerns and Weak Consumer Sentiment

29 de ago. de 2026, 22:52 UTC

Brazil's Q2 GDP Growth Rate Release on September 1, 2026, Sparks Cautious Market Anticipation Amid Global Economic Uncertainties.

29 de ago. de 2026, 22:51 UTC

Correlated Moves

Barclays reports a potential commodity shock from adverse weather and underinvestment. In after-market trading, Silver Ounce vs Euro is roughly flat near its one-month range.

29 de ago. de 2026, 22:41 UTC

Upcoming MBA Mortgage Rate Release Sparks Cautious Investor Sentiment Amid Inflation and Fed Hike Expectations

29 de ago. de 2026, 22:11 UTC

Germany's Inflation Rate Expected to Rise to 2.9% in August Amid Fed Concerns Over Elevated Prices

29 de ago. de 2026, 22:11 UTC

Germany's Inflation Rate Release on August 31 Sparks Investor Caution Amid Persistent Price Pressures and Potential Monetary Policy Tightening.

29 de ago. de 2026, 22:11 UTC

Japan's Q2 2026 Capital Spending YoY data set for release, with a modest growth forecast of 0.2% amid cautious investor sentiment and rising inflation concerns.

29 de ago. de 2026, 21:51 UTC

Japan's Industrial Production Expected to Contract 0.006% in July Amid Mixed Economic Sentiment and Rising Inflation Concerns

29 de ago. de 2026, 21:51 UTC

Japan's Retail Sales YoY data for July 2026 expected to rise by 0.3% amid mixed economic signals and wavering investor confidence ahead of the release on August 30, 2026.

29 de ago. de 2026, 21:41 UTC

South Africa's Business Confidence Index set for release amid cautious market sentiment following significant declines and ongoing geopolitical uncertainties.

29 de ago. de 2026, 21:41 UTC

Australia's Ai Group Industry Index set for release on September 1, 2026, amid cautious expectations of continued industrial contraction due to high costs and subdued demand.

29 de ago. de 2026, 21:41 UTC

South Korea's Upcoming Inflation Rate Release on September 1, 2026, Expected to Impact Economic Outlook Amid Mixed Market Sentiment and Global Price Pressures.

29 de ago. de 2026, 21:31 UTC

API Crude Oil Stock Change Data Release on September 1, 2026, Expected to Impact U.S. Market Amid Rising Inventories and Geopolitical Tensions

29 de ago. de 2026, 20:41 UTC

India's Q2 2026 GDP Growth Rate Forecast at 7.1% Amid Cautious Optimism and Global Economic Pressures

29 de ago. de 2026, 20:31 UTC

Euro Area Retail Sales Expected to Rise 0.3% in July Amid Mixed Economic Signals and Caution from Spain's Decline

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

55.35% parte superior

Previsão para 12 meses

Média 53.86 USD 55.35%

Máximo 60 USD

Mínimo 45 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.